Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499
Sign Up to like & getrecommendations! Published in 2017 at "Leukemia"
DOI: 10.1038/leu.2016.305
Abstract: Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90 Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499 read more here.
Keywords: initial therapy; abbreviated chop; mantle cell; therapy abbreviated ... See more keywords
Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival
Sign Up to like & getrecommendations! Published in 2021 at "European Journal of Haematology"
DOI: 10.1111/ejh.13649
Abstract: While most patients with mantle cell lymphoma (MCL) receive therapy shortly after diagnosis, a subset of patients with indolent‐behaving disease can safely defer treatment. In this subgroup, we evaluated the importance of treatment intensity in… read more here.
Keywords: intensive induction; mantle cell; initial therapy; cell lymphoma ... See more keywords
Compositional alterations of gut microbiota in children with primary nephrotic syndrome after initial therapy
Sign Up to like & getrecommendations! Published in 2019 at "BMC Nephrology"
DOI: 10.1186/s12882-019-1615-4
Abstract: BackgroundPrimary nephrotic syndrome (PNS) is a common glomerular disease in children. T cell dysfunction plays a crucial role in the pathogenesis of PNS. Moreover, dysbiosis of gut microbiota contributes to immunological disorders. Whether the initial… read more here.
Keywords: therapy; gut microbiota; initial therapy; pns ... See more keywords
Differential response to carfilzomib based on initial therapy with bortezomib in multiple myeloma.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e19515
Abstract: e19515Background: Proteasome inhibitors (PIs) are efficacious in multiple myeloma (MM). In randomized phase 3 studies Carfilzomib doubled the progression free survival (PFS) compared to Bortezomib ... read more here.
Keywords: initial therapy; response carfilzomib; differential response; multiple myeloma ... See more keywords